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Background: Although antiplatelet therapy involving clopidogrel is a standard treatment for preventing cardiovascular
events after coronary stent implantation, patients can display differential responses. Here, we assessed the effectiveness
of clopidogrel on platelet function inhibition in subjects with and without type-2 diabetes and stable coronary artery
disease. In addition, we investigated the correlation between platelet function and routine clinical parameters.
Methods: A total of 64 patients with stable coronary heart disease were enrolled in the study. Among these, 32 had
known type-2 diabetes, whereas the remaining 32 subjects were non-diabetics (control group). A loading dose of
300 mg clopidogrel was given to clopidogrel-naïve patients (13 patients in the diabetes group and 14 control patients).
All patients were given a daily maintenance dose of 75 mg clopidogrel. In addition, all patients received 100 mg ASA
per day. Agonist-induced platelet aggregation measurements were performed on hirudin-anticoagulated blood using
an impedance aggregometer (Multiple Platelet Function Analyzer, Dynabyte, Munich, Germany). Blood samples
were drawn from the antecubital vein 24 h after coronary angiography with percutaneous coronary intervention. The
platelets were then stimulated with ADP alone or ADP and prostaglandin-E (ADP and ADP-PGE tests, respectively) in
order to evaluate clopidogrel-mediated inhibition of platelet function. The effectiveness of ASA was measured by
stimulation with arachidonic acid (ASPI test). In addition, maximal platelet aggregation was assessed via stimulation
with thrombin receptor-activating peptide (TRAP test).
Results: Patients with diabetes exhibited significantly less inhibition of platelet function than patients without diabetes
(ADP-PGE test p = 0.003; ASPI test p = 0.022). Administering a clopidogrel loading dose of 300 mg did not result in a
lower level of ADP-PGE-induced platelet reactivity in comparison to the use of a 75 mg maintenance dose. Moreover,
we observed that ADP-PGE-induced platelet inhibition was positively correlated with fasting blood glucose and HbA1c
(p < 0.01).
Conclusions: Patients with type-2 diabetes exhibited increased platelet reactivity compared to patients without
diabetes despite combined treatment with clopidogrel and ASA. Using a loading dose of clopidogrel rather than small
daily doses was not sufficient for adequately overcoming increased platelet reactivity in patients with type-2 diabetes,
highlighting the need for more effective anti-platelet drugs for such patients.
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Table 1 Patient characteristics
Control Diabetes
(n = 32) (n = 32)
Age (y) 64.8 ± 12.5 70.2 ± 8.2
Sex (% women) 21.9 21.9
Platelets (nl) 248.5 ± 89.4 223.0 ± 75.4
BMI (kg/m2) 25.5 ± 3.2 30.0 ± 5.4
Leucocytes (nl) 6.9 ± 1.8 7.5 ± 2.5
HbA1c (%) 5.6 ± 0.3 7.2 ± 1.2
Fasting blood glucose (mg/dl) 84 ± 16.0 151 ± 33.1
CRP (mg/dl) 0.6 ± 1.5 0.8 ± 1.7
Cholesterol (mg/dl) 160 ± 33.5 157 ± 39.3
Triglycerides (mg/dl) 150 ± 69.9 165 ± 51.2
HDL-cholesterol (mg/dl) 45.8 ± 11.3 46.8 ± 18.9
LDL-cholesterol (mg/dl) 95.1 ± 24.1 98.2 ± 28.8
Concomitant drugs
Statin (%) 96.9 100
CCB (%) 90.1 65.6
ASA-100 mg/d (%) 100 100
Antidiabetic drugs
Metformin (%) 0 59.4
Insulin (%) 0 31.3
Other/none (%) 0 25.0
Clopidogrel
Loading dose-300 mg (%) 43.8 40.6
Maintenance dose-75 mg/d (%) 100 100
Legend: BMI, body mass index; HbA1c, glycated hemoglobin; CRP, C-reactive
protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CCB,
calcium channel blocker; ASA, acetylsalicylic acid.
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Combined antiplatelet therapy using acetylsalicylic acid
(ASA) and clopidogrel is the standard therapy regimen
for secondary prevention of cardiovascular events after
coronary stent implantation in patients with stable cor-
onary artery disease [1-3]. However, variable inter- and
intra-individual responses to clopidogrel (i.e., “clopido-
grel low responsiveness”) represent a significant clinical
limitation [4,5]. In addition, various drug interactions
have been reported to affect clopidogrel-mediated inhib-
ition of platelet function [6-8]. Notably, inefficient suppres-
sion of platelet activity upon treatment with clopidogrel
and ASA has been associated with significantly increased
cardiovascular risk [9,10].
In 2000, we reported that shear-stress-induced thrombus
formation on the tunica media of an injured blood ves-
sel was significantly increased when blood was obtained
from patients with type-2 diabetes as compared to non-
diabetics [11]. Moreover, we found that hyperglycemia
and leukocyte count positively correlated with increased
thrombus formation [11], and that intensive glycemic
control in patients with type-2 diabetes was effective in
decreasing blood thrombogenicity [12]. We also dem-
onstrated that diabetic cardiovascular autonomic neur-
opathy and diabetic angiopathy were associated with
increased platelet activation, possibly contributing to
the pathogenesis of these conditions [13,14]. Addition-
ally, it has previously been shown that mean platelet
volume increases with increasing fasting blood glucose
[15]. Thus, these alterations may collectively contribute
to the association between poor glycemic control and
poor outcome in patients undergoing percutaneous
coronary intervention [16].
The response of patients with type-2 diabetes to
anti-aggregatory therapy has therefore recently become
an important topic of investigation. Indeed, Geisler et al.
studied the effect of a 600 mg clopidogrel loading dose
in patients with acute coronary syndrome with or with-
out type-2 diabetes [17]. They reported that diabetic
patients displayed a significantly higher risk for further
atherothrombotic complications resulting from insuffi-
cient inhibition of platelet aggregation, and increased
blood thrombogenicity. In addition, Angiolillo et al.
found that clopidogrel withdrawal is associated with an
increase in platelet and inflammatory biomarkers in
diabetic patients [18].
In the present study, we examined the effect of com-
bined treatment with clopidogrel and ASA on platelet
function inhibition using impedance aggregometry.
We compared agonist-induced platelet aggregation in
patients with stable coronary artery disease with and
without type-2 diabetes. Moreover, we evaluated the
correlation between metabolic parameters and measures
of platelet function.Methods
Patients and anti-platelet medication strategies
This study included 64 consecutively enrolled patients
with coronary heart disease and stable angina pectoris.
Patients were included if they were aged 40 to 75 years,
were receiving a statin along with ASA, and had been
selected to undergo clopidogrel treatment at the discre-
tion of their physician. Patients were excluded if they
had experienced a myocardial infarction within the last
28 days; displayed elevation in troponin T or creatinine
kinase; had been receiving long-term anticoagulation
therapy; had known cancer, liver cirrhosis, or dialysis-
dependent renal failure; were receiving antibiotic ther-
apy; were pregnant; or were alcohol-dependent. Among
the enrolled subjects, 32 patients had a confirmed diag-
nosis of type-2 diabetes and 32 patients were diabetes
free. An oral glucose tolerance test was employed to
exclude the presence of diabetes in the control group.
The patient characteristics, concurrent medications, and
laboratory blood test results are given in Table 1. All
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In the control group, 18 patients received 75 mg of
clopidogrel once daily; in the diabetes group, 19 received
75 mg of clopidogrel once daily. The day prior to
undergoing percutaneous coronary intervention (PCI), a
300 mg loading dose of clopidogrel was given to the 14
clopidogrel-naïve patients in the control group and the
13 in the diabetes group. Subsequently, all 64 patients
were administered a maintenance dose of 75 mg clopi-
dogrel per day. All patients received unfractionated hep-
arin (UFH) during the catheterization. Platelet function
was measured in all patients 24 h after coronary angiog-
raphy and PCI (Figure 1). This study was approved by
the local ethics committee, and all patients gave informed
consent prior to study inclusion.
Assessing inhibition of platelet function
Venous blood was collected in test tubes containing hiru-
din (25 μg/ml), which allowed for inhibition of coagulation
without affecting calcium levels. Platelet function was
then analyzed using a Multiple Platelet Function Analyzer
(Multiplate-Test, Dynabyte, Munich, Germany), which
measures increases in impedance [19]. In brief, activated
platelets adhere to sensor surfaces within the system and
aggregate to form a barrier, which results in a constant in-
crease in resistance between the electrodes. The extent of
aggregation was measured over a period of 6 min and was
calculated based on the area under the curve (AUC) [20].
Whole blood was first diluted with 0.9% NaCl at a ratio of
1:1 and then stored for 3 min in the test cell at 37°C. Sub-
sequently, several reagents were added to induce platelet
aggregation: 1) adenosine diphosphate (ADP, final concen-
tration: 6.4 μmol/l) for assessment of ADP-dependent
platelet aggregation; 2) ADP and prostaglandin-E (ADP-
PGE, 6.4 μmol/l) for measuring the effectiveness of the
P2Y12-receptor antagonist clopidogrel; 3) arachidonic acid
(0.5 mmol/l, ASPI test) for evaluating the effectiveness of
ASA on platelet function; and 4) thrombin receptor-
activating peptide (TRAP; final concentration: 32 μmol/l)75 mg/d 75 mg/d
All patients on asa 100 mg/d
300 m
Figure 1 Clinical study design. Legend: Schematic representation of the
without type-2 diabetes were enrolled. A 300 mg loading dose of clopidog
given a daily maintenance dose of 75 mg clopidogrel. In addition, all patie
drawn 24 h after coronary angiography with percutaneous coronary interv
were performed.for stimulating thrombin receptors on platelets to induce
maximal platelet aggregation.Definition of low responsiveness to clopidogrel
ADP-induced platelet aggregation as measured by im-
pedance aggregometry has been shown to correlate well
with that measured using the vasodilator-stimulated
phosphoprotein (VASP) phosphorylation test, which is
considered to be the gold standard for detecting clopido-
grel low responders [21]. Based on this prior comparison
by Stellbaum et al., we pre-defined clopidogrel low-
responders as those with platelet aggregation above the
75th percentile (cut-off of 27 AUC for the ADP test or
10 AUC for the ADP-PGE test; data not shown).Statistical methods
As there were no comparable studies that could be
used to obtain effect sizes at the time of designing the
study, no power analysis for sample size calculation
could be carried out. Therefore, we aimed to enroll at
least n1 = n2 = 30 patients in both groups to ensure the
proper conduct of parametric test statistics (i.e. robust-
ness against violations of the assumptions of normality
and variance homogeneity) to obtain the associated
sensitivity.
To test for significant differences between the two
groups a Student’s t-test for independent samples was
used. In case of subsequent analyses with smaller and/or
unequal sample sizes, we used the Mann–Whitney test
statistic. To test for significant correlations, Pearson’s
correlation coefficient was calculated and tested for
significance as this test statistic reacts robustly to viola-
tions of the assumed bivariate normal distribution when
tested against a null hypothesis of ρ = 0. All reported
probability values are two-sided, and a value of p < 0.05
was considered to indicate statistical significance. Statis-
tical analyses were carried out using SPSS software, ver-





Patients treated with a clopidogrel loading 
Patients on maintenance clopidogrel 
study design. Patients presenting stable coronary heart disease with or
rel was given to clopidogrel-naïve patients. All other patients were
nts received acetylsalicylic acid (ASA; 100 mg/day). Blood samples were






















Controls (n=32) Diabetes (n=32)
P<0.05
Figure 3 TRAP-induced platelet aggregation in patients with and
without diabetes. Legend: Agonist-induced platelet aggregation
measurements were performed on blood samples from diabetic
and non-diabetic patients through impedance aggregometry. Maximal
platelet aggregation was assessed via stimulation with thrombin
receptor-activating peptide (TRAP). P values were calculated using
a student’s t-test for independent samples.
Schuette et al. Cardiovascular Diabetology  (2015) 14:15 Page 4 of 7Results
In the present study, we enrolled 64 patients with stable
coronary heart disease. Among them, 32 had known
type-2 diabetes, whereas the remaining 32 subjects were
non-diabetics (control group). The characteristics of
these patients are presented in Table 1.
ADP- and ADP-PGE-induced platelet reactivity was
found to be significantly higher in patients with type-2
diabetes compared to control patients, despite treatment
with clopidogrel and ASA (Figure 2; ADP test: p = 0.003;
ADP-PGE test: p = 0.004). Notably, 31% of the patients
with type-2 diabetes exhibited ADP-induced platelet
reactivity above 27 AUC, which was defined as clopido-
grel low responsiveness. In contrast, only 6.4% of the pa-
tients without diabetes were classified as low responders
(Figure 2A).
Considering TRAP-induced platelet reactivity, there
was significantly higher platelet reactivity observed in
the diabetes group when compared to non-diabetic
patients (Figure 3, p < 0.05). In line with this, arachi-
donic acid-induced platelet reactivity (ASPI test) was
significantly elevated in patients with diabetes (Figure 4,
p = 0.01).
When comparing platelet aggregation in both groups
after administration of a clopidogrel loading dose
(300 mg), patients with type-2 diabetes continued to
exhibit significantly higher ADP- and ADP-PGE-induced
platelet reactivity compared to patients without diabetes
(Figure 5A).
Finally, we observed that ADP-PGE-induced platelet
aggregation positively correlated with fasting blood
glucose (r = 0.37; p < 0.001) and HbA1c level (r = 0.36;
p < 0.005).
Discussion
Our findings indicate that combined treatment with clo-







































Controls (n=32) Diabetes (n=32)
P=0.003
Figure 2 ADP- and ADP-PGE -induced platelet aggregation in patient
aggregation measurements were performed on blood samples from diabe
platelets were stimulated with adenosine diphosphate (ADP; A) alone or A
a student’s t-test for independent samples.diabetes than in those without. It is clear from the litera-
ture that there are many different factors that can have
an effect on platelet reactivity in diabetic patients. Mor-
tensen et al. found that diabetic patients with coronary
heart disease displayed higher levels of sP-selectin than
did non-diabetics, indicating increased platelet reactivity
and higher cardiovascular risk [22]. A study by Erlinge
et al. demonstrated that decreased response to clopido-
grel by diabetic patients was likely due to a reduction in
the amount of circulating active metabolite [23]. This in-
dicates inefficient transformation of clopidogrel into the





































Controls (n=32)       Diabetes (n=32)
P=0.004
s with and without diabetes. Legend: Agonist-induced platelet
tic and non-diabetic patients using an impedance aggregometer. The























Controls (n=32) Diabetes (n=32)
P<0.01
Figure 4 ASPI test in patients with and without diabetes.
Legend: Platelet aggregation measurements were performed on blood
samples from diabetic and non-diabetic patients using an impedance
aggregometer. The effectiveness of acetylsalicylic acid (ASA) was
measured by stimulation with arachidonic acid (ASPI test). P values
were calculated using a student’s t-test for independent samples.
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risk in patients with type-2 diabetes has been shown to
be related to higher levels of certain inflammatory
markers [24,25]. Geisler et al. reported that diabetic
patients with hyperglycemia had increased amounts of
such markers in comparison to normoglycemics and
non-diabetic patients [26]. Moreover, they showed that
higher levels of inflammatory markers correlated with
decreased response to ASA and clopidogrel dual therapy.
Recently, Rosiak et al. reported decreases in a number of
inflammatory markers in patients with type-2 diabetes on
either raising the daily dosage of ASA or replacing ASA
with clopidogrel [27]. Furthermore, they found that the
effects were reduced in patients with poor long term gly-





































Controls (n=14)       Diabetes (n=13)
P=0.045
Figure 5 ADP/PGE-induced platelet aggregation after clopidogrel loa
patients. Legend: Agonist-induced platelet aggregation measurements we
The platelets were stimulated with adenosine diphosphate and prostagland
of platelet function after a 300 mg loading dose (A), and after a 75 mg ma
were calculated using a student’s t-test for independent samples.in patients with type-2 diabetes in comparison to those
without the condition. This has been speculated to be a
cause of decreased efficacy of ASA therapy in diabetic pa-
tients [28]. Similarly, increased esterase activity in younger
patients has been linked to reduced bioavailability of ASA,
resulting in high platelet reactivity [29].
Although it is well accepted that platelet aggregation in-
hibition is necessary for patients with type-2 diabetes [30],
there remains a need to develop more effective antiplatelet
therapies [31]. Patients with diabetes are known to display
increased populations of circulating platelets that express
activation-dependent adhesion molecules that may con-
tribute to increased aggregation and might provide new
pharmacological targets [32]. Also, transient receptor po-
tential canonical type 6 (TRPC6) calcium channels in-
crease on platelets in response to high glucose [33], and
could represent a novel target. Moreover, investigating the
role of platelet-derived tissue factor-positive microparticles
as well as adipose tissue-secreted hormones may be inter-
esting with regard to therapeutic potential [34,35]. Indeed,
leptin, resistin, and adiponectin have all been found to be
increased in diabetic patients [35,36]. Thus, further re-
search will be needed to assess these molecules as possible
targets for novel antiplatelet therapies.
In addition, currently existing therapies could also be
beneficial for diabetic patients. For example, we recently
compared periprocedural platelet reactivity after adminis-
trating either bivalirudin, which directly binds to thrombin
(the most effective activator of platelets), or unfractionated
heparin during PCI, finding that bivalirudin was better
than heparin at reducing platelet activation [37]. Thus, the
efficacy of bivalirudin could be tested in diabetic patients
and compared to current treatment approaches. Moreover,
ADP receptor inhibitors (other than clopidogrel) have





































ding and maintenance doses in diabetic and non-diabetic
re performed on blood samples through impedance aggregometry.
in (ADP-PGE) in order to evaluate clopidogrel-mediated inhibition
intenance dose (B) in patients with and without diabetes. P values
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was superior to prasugrel for reducing platelet reactivity
in subjects with acute coronary syndrome and diabetes
[38,39]. However, whether this higher potency of ticagrelor
will translate into a clinical benefit for diabetic patients re-
mains to be investigated. Nevertheless, it is interesting that
treatment with ticagrelor led to a significant reduction
in the rate of death from vascular causes, myocardial in-
farction, or stroke when compared to clopidogrel in acute
coronary syndrome patients [40].
In the present study, we demonstrated that even a
300 mg loading dose of clopidogrel did not provide as ef-
fective platelet inhibition in patients with diabetes as that
achieved in those without. Similar results were achieved
by Angiolillo et al., who reported increased platelet re-
activity in diabetic compared to non-diabetic patients,
both after long term ASA/clopidogrel dual therapy and
after a 300 mg loading dose, prior to PCI [31]. However,
Sibbing et al. used a higher loading dose of 600 mg, and
found no significant difference in platelet reactivity be-
tween diabetic and non-diabetic patients [41]. Thus, a
significant proportion of patients with type-2 diabetes
could display an insufficient therapeutic effect when
treated with long term daily clopidogrel doses of 75 mg
prior to PCI. A more recent study by Angiolillo et al.
compared a 600 mg loading dose of clopidogrel to a
60 mg loading dose of prasugrel [42]. They found higher
anti-platelet response in diabetic patients treated with
prasugrel, in addition to a superior response profile.
In combination, these results suggest that the use of
alternative therapies such as ticagrelor or prasugrel
could provide superior reductions in platelet reactivity
in diabetic patients who do not respond sufficiently to
clopidogrel.
Here, we observed that ADP-PGE-induced platelet ag-
gregation positively correlated with fasting blood glucose
and HbA1c. We have previously documented a correl-
ation between thrombogenicity and blood glucose levels
in type 2 diabetics [11]. Furthermore, we showed that a
reduction in HbA1c level was associated with a reduc-
tion in blood thrombogenicity [12]. Angiolillo et al. add-
itionally showed that patients with inefficiently regulated
blood glucose exhibited a lower response to clopidogrel,
along with increased blood thrombogenicity [31]. How-
ever, a significant relationship between ASPI-induced
platelet aggregation and fasting blood glucose or HbA1c
has not yet been reported. Thus, our results point to an
association between actual glucose level and platelet
reactivity, although further studies on a larger scale and
including assessment of ASPI-induced aggregation are
necessary before accurate conclusions can be drawn.
Thus, glycemic control might favor a better response to
anti-platelet therapies such as clopidogrel in patients
with type-2 diabetes.There are a number of limitations to this study. The
low number of patients enrolled resulted in there being
fewer than 20 in each of the four groups, with only 13 in
the group consisting of diabetic patients receiving the
clopidogrel loading dose. A further limitation is that
platelet reactivity was not measured prior to initiating
clopidogrel therapy. This was because patients were
already receiving anticoagulation treatment with ASA.
Conclusions
In summary, we have examined platelet activity utilizing
impedance aggregometry, which represents a simple and
fast method to assess inhibition of platelet function.
Patients with type-2 diabetes exhibited an increased
platelet reactivity compared to patients without diabetes,
despite combined treatment with clopidogrel and ASA.
Increasing clopidogrel dose was not sufficient for redu-
cing the increased platelet reactivity in patients with
type-2 diabetes, highlighting the need to further investi-
gate other anti-platelet drugs in this population.
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